• 1
    Greely H., Sahakian B., Harris J., Kessler R. C., Gazzaniga M., Campbell P. et al. Towards responsible use of cognitive-enhancing drugs by the healthy. Nature 2008; 456: 7025.
  • 2
    Sahakian B., Morein-Zamir S. Professor's little helper. Nature 2007; 450: 11579.
  • 3
    Larriviere D., Williams M. A., Rizzo M., Bonnie R. J. Responding to requests from adult patients for neuroenhancements guidance of the ethics, law and humanities committee. Neurology 2009; 73: 140612.
  • 4
    Bogle K. E., Smith B. H. Illicit methylphenidate use: a review of prevalence, availability, pharmacology, and consequences. Curr Drug Abuse Rev 2009; 2: 15776.
  • 5
    Teter C. J., Falone A. E., Cranford J. A., Boyd C. J., McCabe S. E. Nonmedical use of prescription stimulants and depressed mood among college students: frequency and routes of administration. J Subst Abuse Treat 2010; 38: 2928.
  • 6
    Academy of Medical Sciences. Brain Science, Addiction and Drugs. London: Academy of Medical Sciences; 2008. Available at: (accessed 13 September 2010; archived by webcite at
  • 7
    Outram S. M. The use of methylphenidate among students: the future of enhancement? J Med Ethics 2010; 36: 198202.
  • 8
    De Jongh R., Bolt I., Schermer M., Olivier B. Botox for the brain: enhancement of cognition, mood and pro-social behavior and blunting of unwanted memories. Neurosci Biobehav Rev 2008; 32: 76076.
  • 9
    Van Oorsouw K., Merckelbach H. Expectancies and memory for an emotional film fragment: a placebo study. Am J Psychol 2007; 120: 287301.
  • 10
    Racine E., Forlini C. Expectations regarding cognitive enhancement create substantial challenges. J Med Ethics 2009; 35: 46970.
  • 11
    Svetlov S. I., Kobeissy F. H., Gold M. S. Performance enhancing, non-prescription dose of Ritalin—a comparison with amphetamines and cocaine. J Addict Dis 2007; 26: 16.
  • 12
    Diller L. H. The run on ritalin: attention deficit disorder and stimulant treatment in the 1990s. Hastings Cent Rep 1996; 26: 128.
  • 13
    Advokat C. What exactly are the benefits of stimulants for ADHD? J Atten Disord 2009; 12: 4958.
  • 14
    Singh I., Kelleher K. J. Neuroenhancement in young people: proposal for research, policy, and clinical management. AJOB Neurosci 2010; 1: 316.
  • 15
    Quednow B. B. Ethics of neuroenhancement: a phantom debate. BioSocieties 2010; 5: 1536.
  • 16
    Hall W. Feeling ‘better than well’—can our experiences with psychoactive drugs help us to meet the challenges of novel neuroenhancement methods? EMBO Rep 2004; 5: 11059.
  • 17
    Spillane J. F. Cocaine: From Medical Marvel to Modern Menace in the United States, 1884–1920. Baltimore: Johns Hopkins University Press; 2000.
  • 18
    Rasmussen N. On Speed: The Many Lives of Amphetamine. New York: New York University Press; 2008.